

# Stephen T Sonis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/708213/publications.pdf>

Version: 2024-02-01

171  
papers

13,674  
citations

34105  
52  
h-index

22166  
113  
g-index

176  
all docs

176  
docs citations

176  
times ranked

8378  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Oral Diseases</i> , 2022, 28, 9-22.	3.0	17
2	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 57-77.	329.8	60
3	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. <i>Tumour Virus Research</i> , 2022, 13, 200234.	3.8	4
4	Oral lichen planus: comparative efficacy and treatment costs—a systematic review. <i>BMC Oral Health</i> , 2022, 22, 161.	2.3	20
5	Industry and MASCC—an opportunity not to be missed. <i>Supportive Care in Cancer</i> , 2021, 29, 559-561.	2.2	1
6	Network meta-analysis from a pairwise meta-analysis design: to assess the comparative effectiveness of oral care interventions in preventing ventilator-associated pneumonia in critically ill patients. <i>Clinical Oral Investigations</i> , 2021, 25, 2439-2447.	3.0	2
7	Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. <i>Cancer</i> , 2021, 127, 1796-1804.	4.1	22
8	Treatment for Oral Mucositis—Current Options and an Update of Small Molecules Under Development. <i>Current Treatment Options in Oncology</i> , 2021, 22, 25.	3.0	12
9	Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data. <i>JCO Oncology Practice</i> , 2021, 17, e1668-e1677.	2.9	3
10	Exceptional toxicity resistance. <i>Supportive Care in Cancer</i> , 2021, 29, 2263-2264.	2.2	2
11	Superoxide Dismutase as an Intervention for Radiation Therapy-Associated Toxicities: Review and Profile of Avasopasem Manganese as a Treatment Option for Radiation-Induced Mucositis. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1021-1029.	4.3	15
12	A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment. <i>Supportive Care in Cancer</i> , 2021, 29, 4939-4947.	2.2	18
13	Healthcare-associated infections among patients hospitalized for cancers of the lip, oral cavity and pharynx. <i>Infection Prevention in Practice</i> , 2021, 3, 100115.	1.3	3
14	GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling. <i>PLoS ONE</i> , 2021, 16, e0249343.	2.5	6
15	Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers. <i>Supportive Care in Cancer</i> , 2021, 29, 6061-6068.	2.2	20
16	Disparities in the geospatial distribution of dentists in the United States in 2017. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, e114.	0.4	0
17	The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. <i>Frontiers in Oral Health</i> , 2021, 2, 689386.	3.0	8
18	The application of Omics to accelerate precision medicine in Supportive Care in Cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 7143-7144.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. <i>Diagnostics</i> , 2021, 11, 2207.	2.6	1
20	Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?. <i>Supportive Care in Cancer</i> , 2020, 28, 423-424.	2.2	13
21	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 320-328.	0.8	15
22	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020, 126, 4423-4431.	4.1	540
23	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	2.2	40
24	An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 541-548.	1.8	21
25	Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis. <i>British Dental Journal</i> , 2020, 228, 615-622.	0.6	14
26	Disparities in Oral Cancer Screening Among Dental Professionals: NHANES 2011–2016. <i>American Journal of Preventive Medicine</i> , 2019, 57, 447-457.	3.0	24
27	Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3256-3265.	1.6	77
28	OUP accepted manuscript. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	2.1	34
29	Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 147-154.	4.1	17
30	Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 198-210.	1.3	18
31	Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. <i>Cancer Medicine</i> , 2018, 7, 240-253.	2.8	23
32	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 427-435.	0.8	63
33	Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns. <i>Cancer</i> , 2018, 124, 760-768.	4.1	23
34	Biomarkers Associated with Lymphedema and Fibrosis in Patients with Cancer of the Head and Neck. <i>Lymphatic Research and Biology</i> , 2018, 16, 516-524.	1.1	18
35	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	3.7	57
36	Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 146-151.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. <i>Biotechnology Reports</i> (Amsterdam, Netherlands), 2017, 15, 24-26.	4.4	14
38	The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. <i>EBioMedicine</i> , 2017, 18, 7-8.	6.1	25
39	Genomic data integration in chronic lymphocytic leukemia. <i>Journal of Gene Medicine</i> , 2017, 19, e2936.	2.8	20
40	Extraorally delivered photobiomodulation therapy for prevention of oropharyngeal mucositis in pediatric patients undergoing hematopoietic cell transplantation. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
41	Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 326-339.	1.2	7
42	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 253-260.	0.4	16
43	[P3â€“091]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P968.	0.8	0
44	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	3.5	165
45	Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 469-474.	2.7	10
46	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. <i>Journal of Biotechnology</i> , 2016, 239, 115-125.	3.8	43
47	Pharmacotherapy for the management of cancer regimen-related oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1801-1807.	1.8	61
48	Impact of Microarray Preprocessing Techniques in Unraveling Biological Pathways. <i>Journal of Computational Biology</i> , 2016, 23, 957-968.	1.6	9
49	Design of Biomedical Robots for Phenotype Prediction Problems. <i>Journal of Computational Biology</i> , 2016, 23, 678-692.	1.6	25
50	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. <i>Current Problems in Cancer</i> , 2016, 40, 244-257.	2.0	18
51	Topical Clonazepam Solution for Management of Burning Mouth Syndrome. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, e110.	0.4	0
52	Cytokineâ€“mediated blood brain barrier disruption as a conduit for cancer/chemotherapyâ€“associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016, 139, 2635-2645.	5.1	108
53	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. <i>Supportive Care in Cancer</i> , 2016, 24, 2781-2792.	2.2	179
54	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. <i>Oral Oncology</i> , 2016, 54, 7-14.	1.5	92

#	ARTICLE	IF	CITATIONS
55	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS ONE, 2016, 11, e0152995.	2.5	17
56	Mucositis. Current Opinion in Oncology, 2015, 27, 159-164.	2.4	213
57	Genomics, Personalized Medicine, and Supportive Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 9-16.	3.8	9
58	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. Cancer Treatment Reviews, 2015, 41, 122-128.	7.7	34
59	Mammalian Target of Rapamycin Inhibitorâ€Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 503-508.	2.0	21
60	Oral Medicine referrals at a hospital-based practice in the United States. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 119, 423-429.	0.4	23
61	Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Supportive Care in Cancer, 2015, 23, 433-439.	2.2	13
62	Current understanding of the relationship between periodontal and systemic diseases. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 150-158.	1.1	30
63	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. Journal of Dental Education, 2015, 79, 888-896.	1.2	3
64	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World Journal of Gastroenterology, 2015, 21, 11793.	3.3	29
65	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. Journal of Dental Education, 2015, 79, 888-96.	1.2	0
66	Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Frontiers in Pharmacology, 2014, 5, 51.	3.5	59
67	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	48
68	Multiâ€institutional, randomized, doubleâ€blind, placeboâ€controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer, 2014, 120, 1433-1440.	4.1	57
69	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, 120, 1453-1461.	4.1	838
70	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemotherapy and Pharmacology, 2014, 74, 675-680.	2.3	28
71	Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncology, 2014, 50, 1098-1103.	1.5	25
72	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 2075-2083.	2.2	121

#	ARTICLE	IF	CITATIONS
73	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. <i>Cancer</i> , 2013, 119, 4268-4276.	4.1	107
74	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e236-e240.	3.8	43
75	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e236-e240.	3.8	55
76	Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs).. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-344.	1.6	3
77	Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9530-9530.	1.6	0
78	Randomized double-blind placebo-controlled trial of celecoxib for radiation-induced oral mucositis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9620-9620.	1.6	0
79	Community-based dental evaluation program for hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 143-143.	1.6	1
80	A clinically translatable mouse model for chemotherapy-related fatigue. <i>Comparative Medicine</i> , 2013, 63, 491-7.	1.0	36
81	A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 1797-1804.	2.2	19
82	New Frontiers in Mucositis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 545-551.	3.8	21
83	A Comparison and Assessment of Scoring Scales for Mucositis. , 2012, , 39-46.		3
84	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 735-735.	1.4	0
85	Inflammation and Genetic Risk Indicators for Early Periodontitis in Adults. <i>Journal of Periodontology</i> , 2011, 82, 588-596.	3.4	13
86	The Quest for Effective Treatments of Mucositis. <i>The Journal of Supportive Oncology</i> , 2011, 9, 170-171.	2.3	7
87	Oral mucositis. <i>Anti-Cancer Drugs</i> , 2011, 22, 607-612.	1.4	148
88	Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. <i>Core Evidence</i> , 2010, 4, 199.	4.7	42
89	Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. <i>Cancer</i> , 2010, 116, 210-215.	4.1	131
90	Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. <i>Supportive Care in Cancer</i> , 2010, 18, 95-103.	2.2	39

#	ARTICLE	IF	CITATIONS
91	Regimen-related gastrointestinal toxicities in cancer patients. Current Opinion in Supportive and Palliative Care, 2010, 4, 26-30.	1.3	43
92	Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.. Blood, 2010, 116, 3781-3781.	1.4	0
93	Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncology, 2009, 45, 164-172.	1.5	177
94	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncology, 2009, 45, 1015-1020.	1.5	379
95	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemotherapy and Pharmacology, 2009, 63, 239-251.	2.3	147
96	Oral and Maxillofacial Medicine. Oral Diseases, 2009, 15, 118-118.	3.0	2
97	Links between regimen-related toxicities in patients being treated for colorectal cancer. Current Opinion in Supportive and Palliative Care, 2009, 3, 50-54.	1.3	19
98	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 2008, 62, 33-41.	2.3	179
99	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer, 2008, 113, 2704-2713.	4.1	310
100	Management of Oral Mucositis in Patients Who Have Cancer. Dental Clinics of North America, 2008, 52, 61-77.	1.8	423
101	Efficacy of Superoxide Dismutase Mimetic M40403 in Attenuating Radiation-Induced Oral Mucositis in Hamsters. Clinical Cancer Research, 2008, 14, 4292-4297.	7.0	79
102	Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. International Journal of Radiation Biology, 2008, 84, 401-412.	1.8	29
103	Mucositis: biology and management. Current Opinion in Otolaryngology and Head and Neck Surgery, 2007, 15, 123-129.	1.8	104
104	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 2007, 33, 448-460.	7.7	235
105	Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109, 820-831.	4.1	692
106	Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Supportive Care in Cancer, 2007, 15, 491-496.	2.2	147
107	Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. The Journal of Supportive Oncology, 2007, 5, 231-5.	2.3	27
108	New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care in Cancer, 2006, 14, 516-518.	2.2	47



#	ARTICLE	IF	CITATIONS
109	Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?. Nature Clinical Practice Oncology, 2006, 3, 244-245. Introduction; Oral Care in Advanced Disease; Supportive Care for the Renal Patient; Handbook of Opioid Bowel Syndrome Oral Care in Advanced Disease. Edited by Andrew Davies and Ilora Finley . New York: Oxford University Press, 2005, 221 pp., \$75.00 Supportive Care for the Renal Patient. Edited by E. Joanna Chambers , Michael Germain , and Edwina Brown . New York: Oxford University Press, 2004, 276 pp., \$95.00 (hardcover) Handbook of Opioid Bowel Syndrome. Edited by Chun-Su Yuan , M.D., Ph.D. Bin. Journal of Palliative Medicine, 2006, 9, 814-817.	4.3	3
110	Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. Nature Clinical Practice Oncology, 2005, 2, 134-135.	1.1	0
111	Dimensional Stability of the Alveolar Ridge After Implantation of a Bioabsorbable Bone Graft Substitute: A Radiographic and Histomorphometric Study in Rats. Journal of Oral Implantology, 2005, 31, 68-76.	4.3	18
112	Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05) Reduces the Severity and Duration of Oral Mucositis. Supportive Cancer Therapy, 2005, 2, 122-127.	1.0	5
113	Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens. Biology of Blood and Marrow Transplantation, 2005, 11, 383-388.	0.3	6
114	Palifermin in Myelotoxic Therapy-Induced Oral Mucositis. Drugs, 2005, 65, 2147-2149.	2.0	98
115	Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.. Blood, 2005, 106, 3126-3126.	10.9	1
116	Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).. Blood, 2005, 106, 1343-1343.	1.4	0
117	New trends in the management of oral mucositis. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S54-6.	1.4	0
118	The pathobiology of mucositis. Nature Reviews Cancer, 2004, 4, 277-284.	4.9	0
119	Perspectives on cancer therapy-induced mucosal injury. Cancer, 2004, 100, 1995-2025.	28.4	1,050
120	Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 2004, 100, 2026-2046.	4.1	1,214
121	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 328-336.	4.1	691
122	Pathobiology of mucositis. Seminars in Oncology Nursing, 2004, 20, 11-15.	2.0	136
123	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	1.5	146
124	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	1.4	3
125	Oral mucositis in cancer therapy. The Journal of Supportive Oncology, 2004, 2, 3-8.	1.4	0
126		2.3	88



#	ARTICLE	IF	CITATIONS
127	The prevention and treatment of radiotherapy-induced xerostomia. Seminars in Radiation Oncology, 2003, 13, 302-308.	2.2	24
128	How should we measure and report radiotherapy-induced xerostomia?. Seminars in Radiation Oncology, 2003, 13, 226-234.	2.2	135
129	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer, 2003, 98, 406-412.	4.1	51
130	Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infectious Diseases, The, 2003, 3, 405-412.	9.1	115
131	A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial). Leukemia and Lymphoma, 2003, 44, 1165-1172.	1.3	60
132	Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clinical Cancer Research, 2003, 9, 3454-61.	7.0	40
133	T<scp>he</scp> B<scp>iologic</scp> R<scp>ole for</scp> N<scp>uclear</scp> F<scp>actor</scp> K<scp>appa</scp> B<scp>in</scp> D<scp>isease and its</scp> P<scp>otential</scp> I<scp>nvolvement in</scp> M<scp>ucosal</scp> I<scp>njury</scp> A<scp>ssociated with</scp> A<scp>nti-neoplastic</scp> T<scp>herapy</scp>. Critical Reviews in Oral Biology and Medicine, 2002, 13, 288-289.	4.4	189
134	Nanoparticulate Hydroxyapatite Enhances the Bioactivity of a Resorbable Bone Graft. Materials Research Society Symposia Proceedings, 2002, 735, 641.	0.1	0
135	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood, 2002, 100, 3479-3482.	1.4	167
136	Oral complications of cancer therapy. Oncology, 2002, 16, 680-6; discussion 686, 691-2, 695.	0.5	53
137	Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2001, 19, 2201-2205.	1.6	552
138	Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer, 1999, 85, 2103-2113.	4.1	305
139	Risk factors affecting hospital length of stay in patients with odontogenic maxillofacial infections. Journal of Oral and Maxillofacial Surgery, 1996, 54, 1386-1391.	1.2	75
140	TRANSPLANTATION OF POLARIZED TYPE 2 DONOR T CELLS REDUCES MORTALITY CAUSED BY EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1996, 62, 1278-1285.	1.0	57
141	Section Reviews: Biologicals & Immunologicals: Pharmacological attenuation of chemotherapy-induced oral mucositis. Expert Opinion on Investigational Drugs, 1996, 5, 1155-1162.	4.1	4
142	A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer, 1993, 72, 1612-1617.	4.1	214
143	Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surgery, Oral Medicine, and Oral Pathology, 1993, 76, 45-48.	0.6	35
144	Effect of medical status on dental procedure time. Special Care in Dentistry, 1992, 12, 71-73.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 74, 749-755.	0.6	83
146	An animal model for mucositis induced by cancer chemotherapy. Oral Surgery, Oral Medicine, and Oral Pathology, 1990, 69, 437-443.	0.6	163
147	The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer, 1990, 66, 2375-2379.	4.1	50
148	In vivo and in vitro effects of $\beta$ -carotene and algae extracts in murine tumor models. Nutrition and Cancer, 1989, 12, 371-380.	2.0	7
149	Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surgery, Oral Medicine, and Oral Pathology, 1988, 65, 19-22.	0.6	63
150	Preservation of the alveolar ridge with hydroxyapatite-collagen implants in rats. Journal of Prosthetic Dentistry, 1988, 60, 729-734.	2.8	14
151	An analysis of dental services based in the emergency room. Special Care in Dentistry, 1988, 8, 106-108.	0.8	16
152	Manual of oral and maxillofacial surgery. Special Care in Dentistry, 1988, 8, 40-40.	0.8	0
153	Hospital dentistry: is there a future?. Special Care in Dentistry, 1987, 7, 243-243.	0.8	0
154	Increased efficiency of immunotherapy using irradiated tumor cells. Cancer Immunology, Immunotherapy, 1987, 24, 68-71.	4.2	2
155	Oral complications of multimodality therapy for advanced squamous cell carcinoma of head and neck. Oral Surgery, Oral Medicine, and Oral Pathology, 1986, 61, 139-141.	0.6	22
156	Significance of the head and neck in late infection in renal transplant recipients. Oral Surgery, Oral Medicine, and Oral Pathology, 1986, 62, 524-528.	0.6	1
157	Healing of Spontaneous Periodontal Defects in Dogs Treated with Xenogeneic Demineralized Bone. Journal of Periodontology, 1985, 56, 470-479.	3.4	14
158	Severe oral hemorrhage and sepsis following bone marrow transplant failure. Oral Surgery, Oral Medicine, and Oral Pathology, 1983, 56, 483-486.	0.6	6
159	Interaction of Ia antigen-bearing polymorphonuclear leukocytes and murine splenocytes. Inflammation, 1983, 7, 25-33.	3.8	7
160	The antigenicity of electrocauterized allogeneic tumor cells in mice. Journal of Surgical Research, 1982, 33, 17-22.	1.6	2
161	Effects of supernatants of polymorphonuclear neutrophils recruited by different inflammatory substances on mitogen responses of lymphocytes. Inflammation, 1982, 6, 1-11.	3.8	18
162	Alterations in the Oral Mucosa Caused by Chemotherapeutic Agents.. The Journal of Dermatologic Surgery and Oncology, 1981, 7, 1019-1025.	0.8	113

#	ARTICLE	IF	CITATIONS
163	Utilization of inpatient dental consultation services. <i>Special Care in Dentistry</i> , 1981, 1, 18-21.	0.8	10
164	The Presence of Lymphoblasts in the Gingival Crevice of Children With Acute Lymphoblastic Leukemia. <i>Journal of Periodontology</i> , 1981, 52, 276-279.	3.4	4
165	MODIFICATION OF IN VITRO AND IN VIVO IMMUNE FUNCTION BY ACUTE INFLAMMATORY CELLS. Transplantation, 1980, 30, 244-250.	1.0	10
166	Oral pathoses as diagnostic indicators in leukemia. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1980, 50, 134-139.	0.6	70
167	Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1979, 48, 21-28.	0.6	97
168	Chlorhexidine-Induced Lingual Keratosis and Dysplasia in Rats. <i>Journal of Periodontology</i> , 1978, 49, 585-591.	3.4	18
169	THE ROLE OF EFFECTOR CELLS AND ANTISERUM IN THE INHIBITION OF CELL-MEDIATED CYTOTOXICITY OF ALLOGENEIC TUMOR CELLS. Transplantation, 1976, 22, 52-60.	1.0	2
170	The incidence of mast cells in selected oral lesions. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1972, 34, 245-248.	0.6	10
171	In Vitro Effects of Isobutyl Cyanoacrylate on Four Types of Bacteria. <i>Journal of Dental Research</i> , 1971, 50, 1557-1558.	5.2	36